Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled trial of dapagliflozin for glucocorticoid-induced hyperglycemia in COPD exacerbation
2014-002370-36Phase 4Active
- Sponsor
- Slotervaartziekenhuis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in corticosteroid-induced hyperglycemia (GIH) and chronic obstructive pulmonary disease (COPD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Effectiveness (primary). Started Feb 2015; status: active.
02
Drugs
dapagliflozin
03
Conditions
corticosteroid-induced hyperglycemia (GIH)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-002370-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002370-36.